Company profile for Dewpoint Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a dynamic young biotech company based in Boston and Dresden that is translating brand-new insights about biomolecular condensates into treatments for the toughest diseases. Dewpoint strives to cultivate an inclusive international community that welcomes and empowers everyone. We reject racism, discrimination, harassment, brutality, and all other manifestations of hate. Dewpoint Therapeutics is the first company founded ...
We are a dynamic young biotech company based in Boston and Dresden that is translating brand-new insights about biomolecular condensates into treatments for the toughest diseases. Dewpoint strives to cultivate an inclusive international community that welcomes and empowers everyone. We reject racism, discrimination, harassment, brutality, and all other manifestations of hate. Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
6 Tide Street, Suite 300 Boston, MA 02210
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189301/0/en/FDA-Grants-Fast-Track-Designation-to-Dewpoint-Therapeutics-DPTX3186-for-the-Treatment-of-Gastric-Cancer.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176579/0/en/FDA-Grants-Orphan-Drug-Designation-to-Dewpoint-Therapeutics-DPTX3186-for-the-Treatment-of-Gastric-Cancer.html

GLOBENEWSWIRE
29 Oct 2025

https://www.globenewswire.com/news-release/2025/10/21/3170240/0/en/Dewpoint-Therapeutics-Announces-an-Open-IND-for-First-in-Class-Condensate-Modulator-DPTX3186-for-Wnt-Driven-Cancers.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/10/14/3166238/0/en/Dewpoint-Therapeutics-Announces-Presentation-at-AACR-NCI-EORTC-2025.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/09/10/3148027/0/en/Dewpoint-Therapeutics-Closes-Series-D-Financing-to-Advance-First-in-Class-Condensate-Modulator-c-mod-into-Clinical-Development-for-Gastric-Cancer.html

GLOBENEWSWIRE
10 Sep 2025

https://www.biospace.com/business/dewpoint-slashes-headcount-by-70-as-cash-runway-runs-out

BIOSPACE
08 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty